Disease Information
General Information of the Disease (ID: DIS00189)
| Name |
Urinary tuberculosis
|
|---|---|
| ICD |
ICD-11: 1G80
|
| Resistance Map |
Type(s) of Resistant Mechanism of This Disease
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Catalase-peroxidase (KATG) | [1] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Molecule Alteration | Missense mutation | p.S531L |
||
| Resistant Drug | Isoniazid | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Key Molecule: DNA-directed RNA polymerase subunit beta (RPOB) | [1] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Molecule Alteration | Missense mutation | p.S531L |
||
| Resistant Drug | Isoniazid | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Key Molecule: Catalase-peroxidase (KATG) | [1] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Molecule Alteration | Missense mutation | p.S315T1 |
||
| Resistant Drug | Isoniazid | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Key Molecule: DNA-directed RNA polymerase subunit beta (RPOB) | [1] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Molecule Alteration | Missense mutation | p.S315T1 |
||
| Resistant Drug | Isoniazid | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: DNA-directed RNA polymerase subunit beta (RPOB) | [1] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Molecule Alteration | Missense mutation | p.S531L |
||
| Resistant Drug | Rifampin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Key Molecule: DNA-directed RNA polymerase subunit beta (RPOB) | [1] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Molecule Alteration | Missense mutation | p.S315T1 |
||
| Resistant Drug | Rifampin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
|
|
||||
| Key Molecule: Catalase-peroxidase (KATG) | [1] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Molecule Alteration | Missense mutation | p.S531L |
||
| Resistant Drug | Rifampin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
| Key Molecule: Catalase-peroxidase (KATG) | [1] | |||
| Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
| Molecule Alteration | Missense mutation | p.S315T1 |
||
| Resistant Drug | Rifampin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
| Experiment for Molecule Alteration |
Gene sequencing assay | |||
| Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
References
visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
